Key result
Pravastatin did not reduce the incidence of new-onset atrial fibrillation compared to placebo in older adults at risk of vascular disease (9.8% vs 9.1%; HR 1.08; 95% CI 0.92-1.28; P=0.35).
Why the study?
Does pravastatin reduce the incidence of new onset atrial fibrillation in older individuals with or at risk for vascular disease?
RCT (n=5,804)
double-blind
randomized
Does pravastatin reduce the incidence of new onset atrial fibrillation in older individuals with or at risk for vascular disease?
Hazard Ratio: 1.08 (95% CI 0.92–1.28)
Absolute Event Rate: 9.8% vs 9.1%
p-value: p=0.35
In older patients with or at risk for vascular disease, pravastatin therapy does not prevent new-onset atrial fibrillation, which is instead predicted by baseline ECG abnormalities and older age.
No takes yet. Share an insight, caveat, or question.
Pravastatin should not be used to prevent new-onset AF; confirms lack of benefit in older adults at vascular risk.
Macfarlane et al. (2011) conducted an RCT in history of, or risk factors for, vascular disease (n=5,804). pravastatin vs. placebo was evaluated on development of atrial fibrillation (HR 1.08, 95% CI 0.92-1.28, p=0.35). Pravastatin did not reduce the incidence of new-onset atrial fibrillation compared to placebo in older adults at risk of vascular disease (9.8% vs 9.1%; HR 1.08; 95% CI 0.92-1.28; P=0.35).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: